Skip to main content
. Author manuscript; available in PMC: 2020 May 11.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 Mar 21;11(13):12342–12356. doi: 10.1021/acsami.9b02408

Figure 2.

Figure 2.

In vitro drug toxicity of free (a) talazoparib (IC50 1.412 μM) and (b) buparlisib (IC50 4.722 μM) in 4T1 breast cancer cells. (c) In vitro toxicity of free drugs in combination in 4T1 breast cancer cells. (d) In vitro evaluation of radiosensitization of various MPMs as evaluated by clonogenic assay. Curves are fit using the linear-quadratic equation.